Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxifiban SCHEMBL24336949 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL919675 | 0.98 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL7213400 | 0.94 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL50632 | 0.93 | ITGB3 (0.86) | ITGB3ITGA2B | |
| SCHEMBL7220986 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL7407564 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7413714 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2B | |
| SCHEMBL7214664 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7217243 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B | |
| SCHEMBL7214752 | 0.86 | ITGB3 (0.76) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 954 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521258-B2 | Anticoagulant compounds and methods and devices for their use | ELIXIR MEDICAL CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20250110111-A1 | DISPOSABLE SYSTEM FOR ANALYSIS OF HEMOSTATIC FUNCTION | HEMOSONICS, LLC | 2025-04-03 | — | — | US | claimed |
| EP-4481381-A2 | DISPOSABLE SYSTEM FOR ANALYSIS OF HEMOSTATIC FUNCTION | Hemosonics, LLC (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4439040-A2 | HEPARIN-BASED BLOOD SAMPLER WITHOUT PLATELET ACTIVATION | Radiometer Medical ApS (DK) | 2024-10-02 | — | — | EP | claimed |
| CN-109414452-B | Cyclodextrins as procoagulants | 阿弗隆制药有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-3154343-B1 | RODENT BAIT CONTAINING TWO OR MORE ANTICOAGULATING COMPOUNDS | GULBA DIETRICH (DE) | 2023-10-25 | — | — | EP | claimed |
| US-20230227909-A1 | METHODS OF DETERMINING THE ETIOLOGY OF ACUTE ISCHEMIC STROKES | INSERM INSTITUT NATIONAL DE A SANTE ET DE LA RECH MEDICALE (FR) | 2023-07-20 | — | — | US | claimed |
| US-20230190499-A1 | ANTICOAGULANT COMPOUNDS AND METHODS AND DEVICES FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2023-06-22 | — | — | US | claimed |
| EP-4158656-A1 | METHODS OF DETERMINING THE ETIOLOGY OF ACUTE ISCHEMIC STROKES | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2023-04-05 | — | — | EP | claimed |
| US-20230058634-A1 | PREVENTION OF PLATELET ACTIVATION AND CELL DIFFERENTIATION DURING THE PROCESSING OF BLOOD AND BLOOD-RELATED COMPOSITIONS | ZEON CORPORATION (JP) | 2023-02-23 | — | — | US | claimed |
| EP-1189663-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2002-03-27 | — | — | EP | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-6346517-B1 | ADMINISTERING TINZAPARIN AND ROXIFIBAN | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-12 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| WO-2000053168-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| CN-1259940-A | Crystalline roxifiban | DU PONT MERCK PHARMA (US) | 2000-07-12 | — | — | CN | claimed |
| EP-0991630-A1 | CRYSTALLINE ROXIFIBAN | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| WO-1998057939-A1 | CRYSTALLINE ROXIFIBAN | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | claimed |